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ABSTRACT 
After injury to the central nervous system (CNS), regeneration is often inadequate, except in the case of remyelination. 
This remyelination capacity of the CNS is a good example of a stem/precursor cell-mediated renewal process. Schwann 
cells have been found to act as remyelinating agents in the peripheral nervous system (PNS), but several studies have 
highlighted their potential role in remyelination in the CNS too. Schwann cells are able to protect and support retinal 
cells by secreting growth factors such as brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, and 
basic fibroblast growth factor. Retinal degenerative diseases can be highly debilitating, and they are a major concern in 
countries with an ageing populations. One of the leading causes of permanent loss of vision in the West is a retinal 
degenerative disease known as age-related macular degeneration (AMD). In the United States, nearly 1.75 million people 
over the age of 40 have advanced AMD, and it is estimated that this number will increase to approximately 3 million 
people by 2020. One of the most common pathways involved in the initiation and development of retinal diseases is the 
oxidative stress pathway. In patients with diabetes, Schwann cells have been shown to be able to secrete large amounts 
of antioxidant enzymes that protect the PNS from the oxidative stress that results from fluctuations in blood glucose 
levels. This antioxidant ability may be involved in the mechanism by which Schwann cells are able to promote 
reconstruction in the CNS, especially in individuals with retinal injuries and degenerative diseases. 
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INTRODUCION
After mechanical injury to the central nervous system 
(CNS) or the progression of degenerative diseases of the 
CNS, regeneration is often inadequate because the adult 
CNS is not capable of extensive regeneration. However, 
one exception is myelin regeneration, which is an 
example of stem/precursor cell-mediated CNS 
rehabilitation. This process involves the production of 
multilayer sheaths of myelin (which are outgrowths of 
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glial cells) around the injured axons, and it can 
preserve the function of demyelinated neurons and 
support neurons (1). Research has shown that 
Schwann cells (a type of glial cell) can produce myelin 
in the peripheral nervous system (PNS) and, more 
recently, they have been found to play the same role 
in CNS (based on experimental animal models and 
cases of demyelinating disorders of the CNS in 
humans) (2). PNS Schwann cells are good candidates 
for autologous grafts to demyelinated CNS axons in 
patients with CNS injuries (3) because they are not 
recognized as foreign by the immune system; they are 
an easily accessible source of cells (4); they can 
proliferate in cell culture; and they have a good 
survival rate after transplantation (5). Research on 
models of spinal trauma has showed that after 
transplantation, Schwann cells start to stimulate 
axonal regeneration and support neuronal survival (6). 
There are two types of Schwann cells: myelinating and 
non-myelinating cells. After establishing axonal 
contact, both of these cells are capable of 
dedifferentiation, and they exhibit either myelinating 
or non-myelinating properties based on axonal signals. 
For the survival of mature Schwann cells, there is no 
need for axonal signals, but they are important for the 
survival of immature and precursor Schwann cells. 
Mature Schwann cells have a high degree of plasticity, 
and they are able to regulate their own survival by 
releasing several growth factors (insulin-like growth 
factors (IGFs), platelet-derived growth factor-BB 
(PDGF-BB), and neurotrophin-3 (NT-3)). These growth 
factors play a crucial role in the autocrine circuit that 
leads to the inhibition of apoptosis (7). Unfortunately, 
there is currently no widely recognized, effective 
treatment for sight-threatening retinal degenerative 
diseases such as age-related macular degeneration 
(AMD) and retinitis pigmentosa (RP), which are the 
leading causes of blindness in the world. Although 
many studies have attempted to find a treatment for 
these diseases, there is still no adequate method for 
promoting photoreceptor survival. 
Recently, there has been an interesting proposal to 
deliver appropriate levels of growth factors to the retinas 
of patients with retinal degenerative diseases in order to 
enhance photoreceptor survival. Schwann cells produce 
several factors necessary for photoreceptor survival, 
including bFGF (8), GDNF, BDNF (9), and ciliary 
neurotrophic factor (CNTF) (10). Selection of an 
appropriate source of cells for transplanting into a 
patient with retinal degenerative disease has been a 
major concern because of immune rejection problems 
and logistic and ethical issues. However, Schwann cells 
can be obtained from the recipient’s own tissue, and 
Schwann cell transplants can thereby overcome all of the 
aforementioned problems. Research has shown that 
subretinal injection of Schwann cells in dystrophic Royal 
College of Surgeons (RCS) rats can lead to increases in 
photoreceptor survival time up to 9 months after the 
injection. It appears that the release of growth factors 
(bFGF, GDNF, BDNF, and CNTF (11)) by Schwann cells into 
the subretinal space promotes photoreceptor survival 
and the regeneration of damaged neurons. Furthermore, 
a major strength of using subretinal Schwann cell 
injections is their persistent functional stability after the 
injection, which is evidenced by the positive effect they 
have on visual responsivity in the visual field after the 
injection. 
There are several theories regarding how these Schwann 
cells survive and support the function of photoreceptors 
after sub-retinal delivery injection and do not vanish in a 
new niche. However, the most popular theory is that a 
sheet rapidly forms between the retinal pigment 
epithelium and photoreceptors, which allows the 
Schwann cells to survive and secrete the growth factors. 
Oxidative stress occurs in the natural course of aging, and 
it can lead to high levels of intracellular oxidization. 
When cells are younger, they can overcome oxidative 
stress by increasing the production of defensive 
antioxidants (12). However, eventually, the cells stop 
being able to mitigate the effects of oxidative stress (12). 
Oxidative stress-induced damage can be accelerated and 
become more severe as a result of several environmental 
risk factors including smoking and light exposure. These 
risk factors have also been associated with increases in 
the incidence of retinal degenerative diseases such as 
AMD (13). The damage in AMD is thought to be caused 
by both reactive oxygen species (ROS) and other agents 
such as the lipid peroxidation products 
carboxyethylpyrrole and homocysteine (14, 15). It is 
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believed that antioxidant supplementations and zinc may 
slow down the progression of retinal degenerative 
diseases such as AMD (16, 17). Hypoxia, hyperglycemia, 
and oxidative stress contribute directly and indirectly to 
Schwann cell dysfunction (18). Schwann cells respond to 
oxidative stress as a result of the activation of nuclear 
factor E2-related factor 2 (Nrf2), which is a key 
transcription factor in the antioxidant response pathway. 
In addition to the activation of Nrf2, oxidative stress 
leads to the expression of phase II antioxidant enzymes. 
Hyperglycemia-induced injury can be attenuated in 
dorsal root ganglion (DRG) neurons by stimulating 
caspase 3. Schwann cells can respond to hyperglycemia 
and oxidative stress by further increasing the expression 
of antioxidant enzymes (19). This high degree of 
antioxidant capacity of Schwann cells may help to control 
ROS generated by fluctuations in blood glucose 
concentrations (20). Besides Schwann cells, many cells in 
different parts of body can respond to ROS by initiating 
an antioxidant response. The endogenous antioxidant 
enzymes used to detoxify ROS in the nervous system 
include superoxide dismutase (SOD) (21), heme 
oxygenase (HO-1) (22), catalase (23), glutathione S-
transferase (GST) (24), nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH), and quinone 
oxidoreductase-1 (NQO1) (25). 
Hypotheses 
Previous research has highlighted the promising effect of 
subretinal Schwann cell injections on the survival rate of 
photoreceptors in the retina (11). The mechanism behind 
this effect may be the secretion of growth factors in the 
subretinal space by the Schwann cells (7, 8). However, 
Schwann cells have proven antioxidant effects in the PNS 
of patients with diabetes, and Schwann cell-mediated 
inhibition of oxidative stress in the CNS may underlie the 
improved retinal function after a subretinal Schwann cell 
injection. Thus, we hypothesized that the antioxidant 
capacity of Schwann cells may play a role in reducing 
degenerative retinal damage. A subretinal injection of 
Schwann cells may lead to the release of the antioxidant 
enzymes in response to the oxidative stress present at 
the injection site as a result of the degenerative retinal 
damage. Understanding the possible pathways by which 
Schwann cells reduce CNS damage could help to 
determine which pathways and enzymes to target in 
order to reduce CNS damage further. 
Evaluation of the Hypotheses 
Schwann cells from the sciatic nerves of neonatal rats 
will be cultured using a method developed by Brook et 
al, and the cells will subsequently be purified (26). The 
retina of each rat will be damaged using an injection of 
sodium iodide, and then the rat will be anesthetized. 
Each pupil will be dilated using tropicamide, and a 
suture will be used to stabilize the eye while the 
Schwann cells are injected into the dorso-temporal 
subretinal space by means of either a 30-gauge steel 
needle or a fine glass capillary attached by tubing to a 
10-mL Hamilton syringe. After 8 weeks, a behavioral 
assessment will be carried out using a head-tracking 
method based on an optokinetic test invented by 
Cowey and Franzini (27). The rats will be placed into an 
enclosed clear plastic container surrounded by a motor-
powered drum that can be rotated clockwise and 
counterclockwise. Perpendicular black-and-white lines 
will be arranged in three varying widths, subtending 
0.125, 0.25, and 0.5 cyc/deg. These three sets of lines 
will be shown in a random order to the rats, and they 
will be alternately rotated clockwise and 
counterclockwise, for 60 s in each direction. This test 
will stimulate a subcortical reflex, which in turn will 
stimulate an involuntary head turn in the rats as they 
track the moving lines. To allow precise assessment of 
the movements, the tests will be videotaped. For 
further evaluation, the tests will be repeated at 12 and 
20 weeks after the Schwann cell injections. The 
electrical responses of the retinal cells will be measured 
using electroretinography. Optical coherence 
tomography will be used to study the structure of the 
retinal layers. At 20 weeks after the Schwann cell 
injections, the rats will be anesthetized and killed, the 
eyes will be excised, and the activity of antioxidant 
enzymes (i.e., SOD, HO-1, catalase, and GST) will be 
measured using enzyme-linked immunosorbent assays.  
DISCUSSION 
Schwann cells have been shown to exhibit remyelination 
capabilities in both the PNS and CNS (2). These cells have 
also been shown to secrete growth factors that increase 
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the survival rate of retinal cells (5). Degenerative retinal 
diseases are a major concern in many developed 
countries as a result of their aging populations. One of 
the most widely known pathways responsible for 
degenerative retinal diseases is the oxidative stress 
pathway (13). Increasing the levels of antioxidant 
enzymes and other factors at the site of the damage 
could reduce the rate of retinal degeneration. In patients 
with diabetes, Schwann cells have been shown to protect 
the PNS from oxidative stress that can result from the 
ingestion of large amounts of sugar. Schwann cells can 
also prevent the development of diabetic neuropathy in 
the PNS by activating antioxidant enzymes (20). Figure 1 
helps to explain our hypothesis by showing an innovative 
diagram of the previously identified pathways linked by 
novel connections that may explain the underlying 
mechanism of Schwann cell-mediated preservation of 
vision in retinal degenerative diseases. In addition to the 
previously identified pathways, like growth factor 
secretion, the ability of Schwann cells to protect against 
oxidative stress in the PNS may also reflect the 
mechanism by which retinal cells can be protected by 
injected Schwann cells in patients with degenerative 
diseases. By increasing our understanding of the exact 
mechanisms involved in the protective role of Schwann 
cells in the CNS, this protective ability could eventually be 
augmented by introducing antioxidant enzymes to the 
damaged sites. 
Overview Box 
First question: What do we already know about the 
subject? 
Schwann cells can protect the central nervous system 
and remyelinate injured neurons by secreting growth 
factors. In addition, Schwann cells can reduce the 
adverse effects of oxidative stress in the peripheral 
nervous system by increasing the expression of 
antioxidant enzymes. Second question: What does your 
proposed theory add to the current knowledge available, 
and what benefits does it have? 
Understanding the possible mechanism by which 
Schwann cells can improve the function of injured cells in 
the CNS may result in better management of retinal 
degenerative diseases. For example, if the inhibition of 
oxidative stress is one of the major pathways activated 
after subretinal Schwann cell injections, the use of these 
cells in combination with antioxidants for the treatment 
of early-stage degenerative retinal diseases may inhibit 
the progression of these diseases. 
 
 
Figure 1. Previously identified pathways linked by novel 
connections that may explain the underlying mechanism of 
Schwann cell-mediated preservation of vision in retinal 
degenerative diseases. 
 
Third question: Among numerous available studies, what 
special further study is proposed for testing the idea? 
The most important issue is to distinguish the exact 
antioxidants that play a role in the preservation of vision 
by Schwann cells after subretinal injections. Further 
studies could reveal which cells in the retina respond 
better to the antioxidant effects, and these studies may 
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shed light on how to develop new treatments for 
currently incurable degenerative retinal diseases. 
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